Maat Pharma SA risk profile
44 Elevated one input has moved against it
Measured 1 September 2026 from MAAT's filed statements. Recomputed nightly.
44 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 84 | Acute | Volatile | One-year price volatility — 90.4% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -32.4 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.04x |
| Leverage and coverage | 42 | Elevated | Stable | Interest cover — -22.26x |
| Competitive position | 45 | Elevated | Stable | Operating-margin gap against peers — -561.9 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.